Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

One analyst tracking the biotech upgraded her recommendation on its shares. She now believes that they rate a buy, rather than a hold. 10 stocks we like better than Recursion Pharmaceuticals › An ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Belle Lin: Welcome to Tech News Briefing. It's Tuesday, December 23rd. I'm Belle ...

Jason Chun is a CNET writer covering a range of topics in tech, home, wellness, finance and streaming services. He is passionate about language and technology, and has been an avid writer/reader of ...

Artificial intelligence has become almost impossible to avoid, and for many, it's slowly replacing Google and other search engines. But while ChatGPT and its competitors can be useful, it's important ...